Cargando…
Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
INTRODUCTION: Multiple myeloma remains an incurable plasma cell malignancy which, despite improvements in overall survival over the last decade, is characterized by recurrent relapse and is associated with a poor prognosis. This study investigates the use of novel agents in current real-world clinic...
Autores principales: | Steinmetz, H. Tilman, Singh, Moushmi, Milce, Joseph, Haidar, Mohamad, Rieth, Achim, Lebioda, Andrea, Kohnke, Jörn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918129/ https://www.ncbi.nlm.nih.gov/pubmed/35034310 http://dx.doi.org/10.1007/s12325-021-02022-z |
Ejemplares similares
-
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
por: Weisel, Katja, et al.
Publicado: (2019) -
How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020) -
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)